Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 3
1978 1
1979 1
1980 4
1981 1
1982 1
1983 1
1984 1
1985 1
1987 3
1989 4
1991 5
1992 1
1993 1
1994 3
1995 1
1997 3
1998 4
1999 2
2000 4
2001 4
2002 5
2003 9
2004 11
2005 10
2006 13
2007 12
2008 16
2009 17
2010 11
2011 19
2012 27
2013 36
2014 31
2015 58
2016 49
2017 92
2018 82
2019 73
2020 99
2021 93
2022 95
2023 63

Text availability

Article attribute

Article type

Publication date

Search Results

842 results

Results by year

Filters applied: . Clear all
Page 1
Ulcerative colitis.
Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Kobayashi T, et al. Among authors: ferrante m. Nat Rev Dis Primers. 2020 Sep 10;6(1):74. doi: 10.1038/s41572-020-0205-x. Nat Rev Dis Primers. 2020. PMID: 32913180 Review.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Among authors: ferrante m. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L; International Consortium for Therapeutic Drug Monitoring. Papamichael K, et al. Among authors: ferrante m. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):171-185. doi: 10.1016/S2468-1253(21)00223-5. Lancet Gastroenterol Hepatol. 2022. PMID: 35026171 Free PMC article. Review.
New treatment options for inflammatory bowel diseases.
Verstockt B, Ferrante M, Vermeire S, Van Assche G. Verstockt B, et al. Among authors: ferrante m. J Gastroenterol. 2018 May;53(5):585-590. doi: 10.1007/s00535-018-1449-z. Epub 2018 Mar 19. J Gastroenterol. 2018. PMID: 29556726 Free PMC article. Review.
Vedolizumab for the Treatment of Chronic Pouchitis.
Travis S, Silverberg MS, Danese S, Gionchetti P, Löwenberg M, Jairath V, Feagan BG, Bressler B, Ferrante M, Hart A, Lindner D, Escher A, Jones S, Shen B; EARNEST Study Group. Travis S, et al. Among authors: ferrante m. N Engl J Med. 2023 Mar 30;388(13):1191-1200. doi: 10.1056/NEJMoa2208450. N Engl J Med. 2023. PMID: 36988594 Clinical Trial.
Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening.
Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B, Heremans R, Perneel L, Kobayashi H, Van Zundert I, Brems H, Cox B, Ferrante M, Uji-I H, Koh KP, D'Hooghe T, Vanhie A, Vergote I, Meuleman C, Tomassetti C, Lambrechts D, Vriens J, Timmerman D, Vankelecom H. Boretto M, et al. Among authors: ferrante m. Nat Cell Biol. 2019 Aug;21(8):1041-1051. doi: 10.1038/s41556-019-0360-z. Epub 2019 Aug 1. Nat Cell Biol. 2019. PMID: 31371824
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Ferrante M, et al. Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4. Lancet. 2022. PMID: 35644155 Clinical Trial.
2020 international consensus on ANCA testing beyond systemic vasculitis.
Moiseev S, Cohen Tervaert JW, Arimura Y, Bogdanos DP, Csernok E, Damoiseaux J, Ferrante M, Flores-Suárez LF, Fritzler MJ, Invernizzi P, Jayne D, Jennette JC, Little MA, McAdoo SP, Novikov P, Pusey CD, Radice A, Salama AD, Savige JA, Segelmark M, Shoenfeld Y, Sinico RA, Sousa MJ, Specks U, Terrier B, Tzioufas AG, Vermeire S, Zhao MH, Bossuyt X. Moiseev S, et al. Among authors: ferrante m. Autoimmun Rev. 2020 Sep;19(9):102618. doi: 10.1016/j.autrev.2020.102618. Epub 2020 Jul 12. Autoimmun Rev. 2020. PMID: 32663621 Review.
Efficacy of JAK inhibitors in Ulcerative Colitis.
Ferrante M, Sabino J. Ferrante M, et al. J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S737-S745. doi: 10.1093/ecco-jcc/jjz202. J Crohns Colitis. 2020. PMID: 31879750 Free PMC article. Review.
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR. Sandborn WJ, et al. Among authors: ferrante m. Gastroenterology. 2020 Feb;158(3):537-549.e10. doi: 10.1053/j.gastro.2019.08.043. Epub 2019 Sep 4. Gastroenterology. 2020. PMID: 31493397 Free article. Clinical Trial.
842 results